SORA

Advancing, promoting and sharing knowledge of health through excellence in teaching, clinical practice and research into the prevention and treatment of illness

Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol.

Kenyon, J; Liu, W; Dalgleish, A (2018) Report of Objective Clinical Responses of Cancer Patients to Pharmaceutical-grade Synthetic Cannabidiol. Anticancer Res, 38 (10). pp. 5831-5835. ISSN 1791-7530 https://doi.org/10.21873/anticanres.12924
SGUL Authors: Liu, Wai Man

[img]
Preview
PDF Published Version
Available under License ["licenses_description_publisher" not defined].

Download (241kB) | Preview

Abstract

BACKGROUND/AIM: Cannabinoids are widely used in the management of pain, nausea and cachexia in cancer patients. However, there has been no objective clinical evidence of any anticancer activity yet. The aim of this study was to assess the effects of pharmaceutical-grade synthetic cannabidiol on a range of cancer patients. PATIENTS AND METHODS: We analysed the data routinely collected, as part of our treatment program, in 119 cancer patients over a four-year period. RESULTS: Clinical responses were seen in 92% of the 119 cases with solid tumours including a reduction in circulating tumour cells in many cases and in other cases, a reduction in tumour size, as shown by repeat scans. No side-effects of any kind were observed when using pharmaceutical grade synthetic cannabidiol. CONCLUSION: Pharmaceutical-grade synthetic cannabidiol is a candidate for treating breast cancer and glioma patients.

Item Type: Article
Additional Information: Copyright© 2018, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved
Keywords: Cancer, breast cancer, cannabinoids, ependymoma, prostate cancer, Aged, Antineoplastic Agents, Cannabidiol, Female, Humans, Male, Neoplasms, Pharmaceutical Preparations, Prognosis, Humans, Neoplasms, Cannabidiol, Antineoplastic Agents, Pharmaceutical Preparations, Prognosis, Aged, Female, Male, 1112 Oncology And Carcinogenesis, Oncology & Carcinogenesis
SGUL Research Institute / Research Centre: Academic Structure > Infection and Immunity Research Institute (INII)
Journal or Publication Title: Anticancer Res
ISSN: 1791-7530
Language: eng
Dates:
DateEvent
October 2018Published
21 September 2018Accepted
Publisher License: Publisher's own licence
PubMed ID: 30275207
Go to PubMed abstract
URI: http://sgultest.da.ulcc.ac.uk/id/eprint/110307
Publisher's version: https://doi.org/10.21873/anticanres.12924

Actions (login required)

Edit Item Edit Item